Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (3y) (2015 - 2026)
Powered by 
Analysis
Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | -12.28% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 24.56% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 22.97% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 20.02% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 51.47% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | -7.83% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 29.05% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 17.54% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 41.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.09% |
| Dec 31, 2025 | -31.93% |
| Sep 30, 2025 | 40.93% |
| Jun 30, 2025 | 41.43% |
| Mar 31, 2025 | 30.61% |
| Dec 31, 2024 | 54.54% |
| Sep 30, 2024 | 45.96% |
| Jun 30, 2024 | 58.54% |
| Mar 31, 2024 | 60.60% |
| Dec 31, 2023 | 51.41% |
| Sep 30, 2023 | 66.93% |
| Jun 30, 2023 | 70.09% |
| Mar 31, 2023 | 43.13% |
| Dec 31, 2022 | 30.12% |
| Sep 30, 2022 | 27.22% |
| Jun 30, 2022 | 38.38% |
| Mar 31, 2022 | 48.16% |
| Dec 31, 2021 | 30.25% |
| Sep 30, 2021 | 38.84% |
| Jun 30, 2021 | -13.97% |